Recursion Pharmaceuticals Inc Clas (RXRX)
EBITDA Growth
23.74%
Quarterly · Period ending:
RXRX EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported23.74%period ending
Latest reported23.74%period ending
RXRX Quarterly EBITDA YoY % (-69.13% → 23.74%)
Year-over-year change
High-resolution chart · PNG
RXRX ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| 23.7436% | |
| 44.1566% | |
| 46.3999% | |
| -60.6012% | |
| -66.3657% | |
| -115.6876% | |
| -84.7841% | |
| -2.9386% | |
| -24.6536% | |
| -37.634% | |
| -64.8927% | |
| -48.6935% | |
| -13.3811% | |
| -15.7562% | |
| 13.475% | |
| -28.3012% | |
| -62.7214% | |
| -83.0248% | |
| -162.2893% | |
| -97.9748% | |
| -120.4825% | |
| -69.126% |